Company Listing
Ablynx

Ablynx is discovering and developing novel, proprietary antibody-like molecules called nanobodies. These nanobodies are being developed both as target validation tools and as therapeutics. The unique properties of nanobodies allow them to perform functions that cannot be undertaken by conventional monoclonal antibodies. The company went public in November 2007.

BACK
Location
Ghent, Belgium
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Ablynx is discovering and developing novel, proprietary antibody-like molecules called nanobodies. These nanobodies are being developed both as target validation tools and as therapeutics. The unique properties of nanobodies allow them to perform functions that cannot be undertaken by conventional monoclonal antibodies. The company went public in November 2007.

Location
Ghent, Belgium
Website Address
BACK
 
Copyright Abingworth 2017